BIA webinar recording: Evaluating patient access to rare disease treatments

Watch the recording of Evaluating patient access to rare disease treatments

Approximately 3.5 million people in the UK will be affected by a rare disease at some point in their lifetime. However, approved medicines are available for only 5% of rare diseases. While an area of focus for many healthcare systems, improving access to rare disease treatments is inherently challenging. This means that many patients with rare diseases face high levels of unmet need.

The BIA’s Rare Disease Industry Group (RDIG) has developed a new report that evaluates the current state of play in the UK for access to rare disease treatments, in collaboration with PwC. The report will highlight recent progress that has been made in the UK in improving the lives of people affected by rare diseases, as well as the challenges that remain.

The report will also include an analysis of the approaches taken in other OECD countries to support rare disease treatment access and outline potential learnings for the UK. Watch this webinar to celebrate the launch of the report, and to hear from a panel of experts to discuss the report’s key findings and next steps.

Speakers: